Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients
![]() ![]() |
Joo, Jin-Deok
(Department of Neurosurgery, Seoul National University Bundang Hospital)
Chang, Jong-Hee (Department of Neurosurgery, Severance Hospital, Yonsei University College of Medicine) Kim, Jeong-Hoon (Department of Neurosurgery, Asan Medical Center, University of Ulsan College of Medicine) Hong, Yong-Kil (Department of Neurosurgery, The Catholic University of Korea, Seoul Saint Mary's Hospital) Kim, Young-Hoon (Department of Neurosurgery, Seoul National University Bundang Hospital) Kim, Chae-Yong (Department of Neurosurgery, Seoul National University Bundang Hospital) |
1 | Choi JW, Lee MM, Kim IA, Kim JH, Choe G, Kim CY : The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study. J Korean Neurosurg Soc 44 : 222-227, 2008 DOI |
2 | DeAngelis LM : Brain tumors. N Engl J Med 344 : 114-123, 2001 DOI ScienceOn |
3 | Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. : DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16 : 3851-3857, 1998 DOI |
4 | Ishikawa E, Yamamoto T, Sakamoto N, Nakai K, Akutsu H, Tsuboi K, et al. : Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. Neurol Med Chir (Tokyo) 50 : 638-644, 2010 DOI ScienceOn |
5 | Jeon HJ, Kong DS, Park KB, Lee JI, Park K, Kim JH, et al. : Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas : single-center experience. Clin Neurol Neurosurg 111 : 679-682, 2009 DOI ScienceOn |
6 | Kim YH, Park CK, Cho WH, Kim IA, Moon S, Choe G, et al. : Temozolomide during and after radiation therapy for WHO grade III gliomas : preliminary report of a prospective multicenter study. J Neurooncol 103 : 503-512, 2011 DOI ScienceOn |
7 | Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, et al. : MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated with Temozolomide-Based Chemoradiotherapy : A Single-Institution Study. Int J Radiat Oncol Biol Phys : 2012. Inpress |
8 | Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, et al. : Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12 : 289-296, 2010 DOI ScienceOn |
9 | Park CK, Kim J, Yim SY, Lee AR, Han JH, Kim CY, et al. : Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro Oncol 13 : 195-202, 2011 DOI ScienceOn |
10 | Lakomý R, Fadrus P, Slampa P, Svoboda T, Kren L, Lzicarová E, et al. : [Multimodal treatment of glioblastoma multiforme : results of 86 consecutive patients diagnosed in period 2003-2009]. Klin Onkol 24 : 112-120, 2011 |
11 | Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG : Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277-1280, 1990 DOI |
12 | Omar AI, Mason WP : Temozolomide : The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid 4 : 93-111, 2010 |
13 | Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005 DOI ScienceOn |
14 | Siker ML, Chakravarti A, Mehta MP : Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol 60 : 99-111, 2006 DOI ScienceOn |
15 | Song KS, Phi JH, Cho BK, Wang KC, Lee JY, Kim DG, et al. : Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr 6 : 145-149, 2010 DOI ScienceOn |
16 | Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. : Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20 : 1375-1382, 2002 DOI ScienceOn |
17 | Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. : Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group. J Clin Oncol 28 : 1963-1972, 2010 DOI ScienceOn |
18 | Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. : A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 : 588-593, 2000 DOI ScienceOn |
19 | Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. : Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12 : 259-266, 2001 DOI ScienceOn |
20 | Chibbaro S, Benvenuti L, Caprio A, Carnesecchi S, Pulerà F, Faggionato F, et al. : Temozolomide as first-line agent in treating high-grade gliomas : phase II study. J Neurooncol 67 : 77-81, 2004 DOI |
![]() |